In Europe, medicine shortages are increasingly affecting patient care, with antibiotics for children and routine cancer treatments often unavailable. These shortages are no longer rare events but a growing public concern that affects patient safety, supply chain resilience, and political accountability. Medicine shortages, while not new, are now more visible and harder for health systems to manage. They affect various stakeholders and are rooted in issues like industrial policy, market concentration, regulatory pressures, and fragile global supply chains.
The most frequently affected medicines are commonly used ones, such as basic antibiotics, diabetes medications, certain chemotherapy agents, cardiovascular drugs, pain relief medicines, and emergency care treatments.
-
Antibiotics: Shortages of antibiotics like amoxicillin have drawn attention, especially in pediatric care. When unavailable, doctors must use less familiar alternatives, raising clinical concerns and potentially worsening antimicrobial resistance.
-
Diabetes Medicines: Insulin shortages are critical due to the necessity of continuous access. Supply issues arise from global demand shifts and manufacturing constraints, causing anxiety despite not always resulting in full shortages.
-
Cancer Treatments: These shortages can disrupt precisely timed treatment schedules. Economic factors often drive shortages of low-margin, but essential, generic injectable medicines.
-
Cardiovascular and Critical Care Drugs: Medicines for blood pressure, anticoagulants, anaesthetics, and intensive-care drugs face supply problems, affecting routine and emergency care.
-
Pain and Fever Medicines: Paracetamol and ibuprofen shortages, especially for children, often occur during seasonal surges, triggering public concerns and stockpiling behaviors.
The causes of shortages are multifaceted, including sudden demand increases, manufacturing failures, and global supply chain dependencies. Globalization has improved efficiency but reduced redundancy, and tightly squeezed prices leave little incentive for manufacturers to maintain spare capacity. National pricing strategies can exacerbate vulnerability by prioritizing low costs over resilience. Parallel trade within the European market can also intensify local shortages.
Medicine shortages are a matter of rights and governance, affecting equality, transparency, and state capacity. Patients with resources are better positioned to find scarce medicines, highlighting issues of democratic accountability and transparency in the availability of medicines.
To mitigate these issues, Europe needs better reporting and coordination among national agencies, strategic stockpiles, procurement rules that reward supply security, and diversified manufacturing capacities. Policymakers must distinguish between temporary inconveniences and critical risks, creating targeted strategies for essential medicines. Public scrutiny of market exits and the treatment of medicines as commodities versus necessities require rethinking to address shortages. For Europe to ensure health security, it must prioritize patient needs over market convenience.
Leave a Reply